Pharma BD Deal Intelligence

Shire plc / NPS Pharmaceuticals

2015 · Acquisition/Merger · $5.2B · Complete

The Street Said

Strongly positive — critic reaction at announcement

History Says

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 10

Full analysis, sources & comparables →

The coverage arc

Jan 11, 2015 Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech - PR Newswire Bullish

Shire announced acquisition of NPS Pharmaceuticals for $46 per share in cash, approximately $5.2 billion, to build a leading biotech through rare disease…

Feb 12, 2021 Shire announces US$5.2bn acquisition of NPS Pharmaceuticals - The Pharmaceutical Journal Bullish

Shire announced its $5.2 billion acquisition of NPS Pharmaceuticals to strengthen its rare disease leadership, gaining key products Gattex and Natpara for GI…

Source summaries from our enrichment pipeline; follow links for originals.

All 4 sources with sentiment breakdown →

Shire acquired NPS Pharmaceuticals for $5.2B for rare gastrointestinal diseases.

Key facts

Announced Jan 11, 2015
Closed Feb 21, 2015
Deal value $5.2B
Deal type Acquisition/Merger
Therapeutic area Rare Disease

Related deals — scored

Deal	Year	Value	Outcome
Shire plc / NPS Pharmaceuticals (this deal)	2015	$5.2B	78
Shire plc / Dyax Corp.	2016	$5.9B	89
Shire plc / New River Pharmaceuticals Inc.	2007	$2.6B	88
Shire plc / Jerini AG	2008	$521M	85
Shire plc / Baxalta Inc.	2016	$32.0B	77
Shire plc / ViroPharma Incorporated	2013	$4.2B	58
Shire plc / Movetis NV	2010	$565M	37

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2015 deals · Shire plc deals · Rare Disease deals